CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 500 enrolled
Drug / intervention
Red blood cell transfusionother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00335023
NCT00335023Phase 4Completed
CompareCT.gov

Well Being of Obstetric Patients on Minimal Blood Transfusions

Sanquin Research & Blood Bank Divisions·interventional·Posted Jun 8, 2006·Updated Jul 20, 2011

In Brief

A Phase 4 clinical trial evaluating Red blood cell transfusion for Anemia. Completed, enrolled 500 participants across 1 site.

Detailed Summary

Postpartum haemorrhage (PPH) is one of the top five causes of maternal mortality in developed and developing countries. The most important treatment of PPH is red blood cell (RBC) transfusion. The decision whether to prescribe RBC transfusion is mostly based on postpartum haemoglobin (Hb) values. RBC transfusion should be aimed to reduce morbidity and especially to improve Health Related Quality of Life (HRQoL). The goal of the WOMB study is to assess the effect of RBC transfusion on HRQoL and to confirm the role of HRQoL in deciding whether RBC transfusion is necessary.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAnemia
CountriesNetherlands
CollaboratorsErasmus Medical Center

Timeline

Phase 4CompletedFinished
200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 8, 2006
Enrollment StartMay 1, 2004
Primary CompletionMar 1, 2011
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 20.1 years ago

Interventions

Red blood cell transfusionother

At least one unit of red blood cells will be administered. The target Hb value after transfusion is at least 8.7 g/dL.